Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
- PMID: 31446393
- PMCID: PMC6951234
- DOI: 10.1136/archdischild-2019-316816
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Erratum in
-
Correction: Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network.Arch Dis Child. 2020 May;105(5):519. doi: 10.1136/archdischild-2019-316816corr1. Epub 2020 Mar 27. Arch Dis Child. 2020. PMID: 32220828 Free PMC article. No abstract available.
Abstract
Objective: To gain an understanding of the variation in available resources and clinical practices between neonatal units (NNUs) in the low-income and middle-income country (LMIC) setting to inform the design of an observational study on the burden of unit-level antimicrobial resistance (AMR).
Design: A web-based survey using a REDCap database was circulated to NNUs participating in the Neonatal AMR research network. The survey included questions about NNU funding structure, size, admission rates, access to supportive therapies, empirical antimicrobial guidelines and period prevalence of neonatal blood culture isolates and their resistance patterns.
Setting: 39 NNUs from 12 countries.
Patients: Any neonate admitted to one of the participating NNUs.
Interventions: This was an observational cohort study.
Results: The number of live births per unit ranged from 513 to 27 700 over the 12-month study period, with the number of neonatal cots ranging from 12 to 110. The proportion of preterm admissions <32 weeks ranged from 0% to 19%, and the majority of units (26/39, 66%) use Essential Medicines List 'Access' antimicrobials as their first-line treatment in neonatal sepsis. Cephalosporin resistance rates in Gram-negative isolates ranged from 26% to 84%, and carbapenem resistance rates ranged from 0% to 81%. Glycopeptide resistance rates among Gram-positive isolates ranged from 0% to 45%.
Conclusion: AMR is already a significant issue in NNUs worldwide. The apparent burden of AMR in a given NNU in the LMIC setting can be influenced by a range of factors which will vary substantially between NNUs. These variations must be considered when designing interventions to improve neonatal mortality globally.
Keywords: antimicrobial resistance; neonatal sepsis.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Antimicrobial resistance: think globally but act locally.Arch Dis Child. 2020 Jan;105(1):1-3. doi: 10.1136/archdischild-2019-317953. Epub 2019 Sep 27. Arch Dis Child. 2020. PMID: 31562183 No abstract available.
References
-
- GARDP.org (internet) Global antibiotic research and development partnership, 2018. Available: www.gardp.org/programmes/neonatal-sepsis/ [Accessed 18 Sep 2018].
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources